EADV 2025｜泛发性脓疱型银屑病的免疫发病机制

大家好，我叫周园，我是来自于浙江大学医学院附属第二医院皮肤科的临床医生。 我们课题组一直关注银屑病的发生发展机制和复发的机制。我们发现很多的泛发性脓疱型银屑病（GPP）患者以前会有一些疾病的病史，也有另一部分人没有银屑病病史，可能一发出来就是 GPP 的表现。 对于 GPP 的治疗，一直都是全世界的难点和重点。既往认为 IL-36 是最重要的治疗方向，但我们在临床过程中发现，有一部分 GPP 患者经过 IL-17 和 IL-23 的治疗，效果非常不错，能够长期持续不复发。 所以对于 GPP 的发生机制，从免疫学机制来看是否存在不同的临床亚型，这是我们比较感兴趣的问题。因此我们对此做了一些研究和总结，相关成果入选了这次的电子海报（eposter），我们感到非常荣幸。 

Hello everyone, my name is Zhou Yuan. I am a clinical doctor from the Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medicine. Our research team has been focusing on psoriasis, specifically on the mechanisms of its occurrence, development, and recurrence. We have found that many patients with Generalized Pustular Psoriasis (GPP) had a history of other diseases before, while another group of patients had no history of psoriasis at all—their first symptom presentation might be GPP itself. The treatment of GPP has always been a key challenge and focus worldwide. Previously, it was believed that IL-36 inhibitors were the most important treatment approach. But in our clinical practice, we have discovered that a subset of GPP patients, after receiving IL-17 or IL-23 targeted therapies, achieved quite positive therapeutic effects with long-term sustained remission and no recurrence. Therefore, regarding the pathogenesis of GPP, we are interested in exploring whether there are different clinical subtypes based on its immunological mechanisms. This is a question that we find very intriguing, so we have conducted relevant research and summarized our findings. Our work has been selected for presentation as an electronic poster (e-poster) at this event, and we are extremely honored.